Valneva Gets EMA Panel's Queries for COVID-19 vaccine VLA2001

Seeking Alpha2022-02-25

Valneva(NASDAQ:VALN)received a list of questions from a committee of the European Medicines Agency (EMA) regarding its COVID-19 vaccine candidate, VLA2001.The company said that it is confident that it...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

jtvcak
2022-02-25
jtvcak
[Like]

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1178002533?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-02-25 17:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178002533","market":"us","top_or_hot":-1,"title":"Valneva Gets EMA Panel's Queries for COVID-19 vaccine VLA2001","media":"Seeking Alpha","content":"<div>\n<p>Valneva(NASDAQ:VALN)received a list of questions from a committee of the European Medicines Agency (EMA) regarding its COVID-19 vaccine candidate, VLA2001.The company said that it is confident that it...</p>\n\n<a href=\"https://seekingalpha.com/news/3805762-valneva-gets-ema-panels-queries-for-covid-19-vaccine-vla2001\">Source Link</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Valneva Gets EMA Panel's Queries for COVID-19 vaccine VLA2001</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nValneva Gets EMA Panel's Queries for COVID-19 vaccine VLA2001\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-02-25 17:49 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3805762-valneva-gets-ema-panels-queries-for-covid-19-vaccine-vla2001><strong>Seeking Alpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Valneva(NASDAQ:VALN)received a list of questions from a committee of the European Medicines Agency (EMA) regarding its COVID-19 vaccine candidate, VLA2001.The company said that it is confident that it...</p>\n\n<a href=\"https://seekingalpha.com/news/3805762-valneva-gets-ema-panels-queries-for-covid-19-vaccine-vla2001\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INRLF","symbol_name":"Valneva SE","start_time":0,"source_url":"https://seekingalpha.com/news/3805762-valneva-gets-ema-panels-queries-for-covid-19-vaccine-vla2001","article_id":"1178002533","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178002533","pubTimestamp":1645782575,"sourceInfo":null,"weMediaInfo":null,"summary":"Valneva(NASDAQ:VALN)received a list of questions from a committee of the European Medicines Agency (","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"INRLF":"Valneva SE"},"translate_title":"瓦涅瓦得到欧洲药品管理局小组对新冠肺炎疫苗VLA2001的质疑","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INRLF":0.9},"content_text":"Valneva(NASDAQ:VALN)received a list of questions from a committee of the European Medicines Agency (EMA) regarding its COVID-19 vaccine candidate, VLA2001.The company said that it is confident that it will be able to respond to the questions by the EMA's Committee for Medicinal Products for Human Use (CHMP) in the coming days.Following the company’s response, the EMA will provide a timetable towards the conditional approval.Valneva expects to receive a positive CHMP opinion for conditional approval of VLA2001 for use in adults 18 to 55 years of age, at the end of Q1 2022.Following such conditional approval, the company expects to deliver the first shipments of VLA2001 to European countries early in Q2 of 2022.Valneva signed an agreement with the European Commission (EC) in November 2021 to supply up to 60M doses of VLA2001 over two years, including 24.3M doses in 20221. The company has begun manufacturing for the EC and Bahraini supply contracts and has inventory ready for labelling and deployment upon regulatory approval.Valneva is currently conducting additional clinical studies aimed at expanding the label and indications of VLA2001 to further age groups, including for potential use as a booster vaccine in 2022.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9030489768,"gmtCreate":1645784661803,"gmtModify":1676534064019,"author":{"id":"4099981318949650","authorId":"4099981318949650","name":"jtvcak","avatar":"https://community-static.tradeup.com/news/7acfb7435979e34ef62125a6c64155d1","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4099981318949650","authorIdStr":"4099981318949650"},"htmlText":"[Like]&nbsp;","listText":"[Like]&nbsp;","text":"[Like]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9030489768","repostId":1178002533,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":17,"commentSize":1,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1178002533"}